Tolerance of Local Administration of Cryopreserved Autologous Stromal Vascular Fraction Combined With Micrograft for the Treatment of Refractory Ano-perineal Fistulas in Crohn's Disease (ADICROHN3)
1 juni 2026 bijgewerkt door: Assistance Publique Hopitaux De Marseille
The ADICROHN-3 study is a prospective, multicenter, open-label cohort study.
Its design is supported by the following elements:
- The results of the ADICROHN pilot study (EudraCT No. 2013-002602-31) and our 3-year study, which demonstrate an excellent safety profile with a promising efficacy signal.
- Data from the literature confirming that cryopreservation of FVS does not compromise the clonogenic and differentiation potential of mesenchymal progenitors, nor its regenerative effect.
- The ongoing ADICROHN-2 study (PHRC N 2019; EudraCT No. 2019-001948-21) confirming the feasibility of patient recruitment, mastery of the therapeutic approach, and the absence of adverse events related to the experimental treatment.
- The opportunity for a second FVS injection for patients initially treated but who did not respond to the treatment.
- The opportunity for a first FVS injection in patients in the placebo arm, thereby providing access to an innovative therapy available to patients included in this trial who are untreated and remain refractory to standard care.
To avoid compromising the results of the ongoing ADICROHN-2 study, enrolled patients will remain blinded to the treatment arm to which they belonged in the ADICROHN-2 study.
Studie Overzicht
Toestand
Werving
Conditie
Interventie / Behandeling
Studietype
Ingrijpend
Inschrijving (Geschat)
25
Fase
- Fase 2
- Fase 1
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
-
Marseille, Frankrijk
- Werving
- APHM Hôpital Nord
-
Contact:
- Dr GUILLO
- Telefoonnummer: +33 0491968737
- E-mail: lucas.guillo@ap-hm.fr
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Nee
Beschrijving
Inclusion Criteria:
- (1) Signing of a consent form.
- (2) Patients with Crohn's disease diagnosed at least 6 months prior, in accordance with clinical, endoscopic, histological, and/or radiological criteria.
- (3) Patients previously enrolled in or treated as part of the ADICROHN 2 study.
- (4) Non-active or mildly active luminal Crohn's disease, defined by a CDAI score ≤ 220.
- (5) Patients who failed to respond to the ADICROHN-2 protocol, defined by the persistence of anoperineal fistula(s) at the end of the ADICROHN-2 study and their persistence at the time of enrollment.
- (6) Patients who achieved success (combined remission) at the end of the ADICROHN-2 study but who have a recurrence of anoperineal fistula(s) at the time of enrollment.
- (7) Sufficient quantity of cryopreserved cells to allow for the innovative treatment, based on the number of fistulas to be treated.
- (8) Patients over 18 years of age.
- (9) Good general health based on medical history and clinical examination.
- (10) Women of childbearing age must have a negative pregnancy test (serum or urine; detection threshold: 25 mIU hCG/ml). Patients of both sexes must use a reliable method of contraception.
- (11) Enrollment in a social security program.
Exclusion Criteria:
- (1) Active, primarily luminal Crohn's disease requiring immediate treatment.
- (2) Patients who experienced intolerance to the advanced therapy medicinal product during the ADICROHN-2 study.
- (3) Presence of an abscess or collections > 2 cm at the time of enrollment, unless this issue is resolved during the fistula preparation period.
- (4) Rectal and/or anal stenosis and/or active proctitis resulting in a limitation of the surgical procedure.
- (5) Patients currently receiving corticosteroids or who have received them within the four weeks prior to the injection of the investigational product.
- (6) Malignant tumors or a history of malignant tumors within the past 5 years.
- (7) Congenital or acquired immunodeficiency.
- (8) Contraindications to local anesthetics and gadolinium (MRI contrast agent).
- (9) Contraindications to MRI: metallic foreign bodies (ferromagnetic material) and metallic implants (pacemakers, heart valves, vascular clips, surgical clips or staples, cochlear implants, any implanted electronic medical device or material [e.g., insulin pump], orthopedic medical prostheses.
- (10) Treatment with darvadstrocel administered < 6 months prior to enrollment)
- (11) Contraindications to general anesthesia.
- (12) BMI < 18 kg/m² to ensure an adequate amount of abdominal adipose tissue or other subcutaneous adipose tissue accessible via manual liposuction.
- (13) Coagulation disorders that contraindicate surgery.
- (14) Known hypersensitivity to human albumin.
- (15) Participation in another clinical trial (excluding observational studies).
- (16) Persons protected under Articles L1121-5, L1121-6, and L1121-8 of the Public Health Code (pregnant or breastfeeding women, persons deprived of liberty by judicial decision, persons in situations of social vulnerability, adults who are legally incapacitated or unable to give informed consent).
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: treatment arm
injection of thawed SVF
|
injection of thawed SVF, collected in ADICROHN 2
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
The primary endpoint of the study is the overall safety profile at 6 months
Tijdsspanne: 6 months
|
absence of local infectious complications, defined by the absence of local signs of inflammation: pain, and/or erythematous plaque, and/or swelling or induration.
|
6 months
|
|
The primary endpoint of the study is the overall safety profile at 6 months
Tijdsspanne: 6 months
|
absence of systemic infectious complications, defined as the absence of systemic signs of infection: fever, chills, mottling, hypotension.
|
6 months
|
|
The primary endpoint of the study is the overall safety profile at 6 months
Tijdsspanne: 6 months
|
absence of any worsening of anal incontinence compared with the pre-treatment assessment, as measured by the Wexner index
|
6 months
|
|
The primary endpoint of the study is the overall safety profile at 6 months
Tijdsspanne: 6 months
|
absence of any other adverse events considered to be potentially related to the experimental treatment.
|
6 months
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
30 december 2025
Primaire voltooiing (Geschat)
29 juni 2028
Studie voltooiing (Geschat)
29 juni 2028
Studieregistratiedata
Eerst ingediend
31 maart 2026
Eerst ingediend dat voldeed aan de QC-criteria
1 juni 2026
Eerst geplaatst (Werkelijk)
5 juni 2026
Updates van studierecords
Laatste update geplaatst (Werkelijk)
5 juni 2026
Laatste update ingediend die voldeed aan QC-criteria
1 juni 2026
Laatst geverifieerd
1 juni 2026
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- RCAPHM22_0449
- 2024-519740-32-00 (Ctis)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .